Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilization in the US.
In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US.
Recent developments in the diagnosis and treatment of HCV, including new recommendations pertaining to screening for HCV by the Centers for Disease Control and Prevention and newer treatment regimens with high efficacy, short duration and the potential for interferon-free therapies, have energized the health care practitioners regarding HCV management.
Dr Younossi and colleagues from Virginia, USA assessed the full impact of HCV burden on clinical, economic and patient-reported outcomes.
|The associations of HCV with type 2 diabetes mellitus is supported by strong evidence |
|Alimentary Pharmacology & Therapeutics|
An expert panel was convened to assess the full impact of HCV burden on a number of important outcomes using an evidence-based approach predicated on Grading of Recommendations Assessment, Development and Evaluation methodology.
The researchers summarized literature, and graded using an evidence-based approach.
Workshop presentations were intended to review recent, relevant evidence-based literature and provide graded summary statements pertaining to HCV burden on topics including the relationships between HCV, and the development of important outcomes.
The researchers noted that the associations of HCV with cirrhosis, HCC, liver-related mortality, type 2 diabetes mellitus, rheumatological diseases and quality of life impairments are supported by strong evidence.
The team found strong evidence that sustained viral eradication of HCV can improve important outcomes such as mortality and quality of life.
Dr Younossi's team comments, "The current evidence suggests that HCV has been associated with tremendous clinical, economic and quality of life burden."